Table 1.

Summary of the nature of the data package submitted and the number of extraordinary meetings (before the conditional marketing authorization was granted) for the different COVID-19 vaccines approved by the European Medicines Agency to date (November 2021).

Sponsor	RR Cycle 1 (Submission Date and Data Package Content)	RR Cycle 2 (Submission Date and Data Package Content)	RR Cycle 3 (Submission Date and Data Package Content)	CMA	No. of Extraordinary Meetings
AstraZeneca	10/1/2020 Nonclinical	12/12/2020 Nonclinical Quality	12/242020	1/122021	2
Pfizer	10/6/2020 Nonclinical	11/7/2020 Quality		12/12020	5
Moderna	11/16/2020 Nonclinical			12/1/2020	2
Janssen	12/1/2020 Nonclinical Clinical	1/25/2021 Nonclinical		2/16/2021	1

CMA = conditional marketing authorization; RR = rolling review.